Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt No Debt
OCRX's Cash to Debt is ranked higher than
88% of the 1248 Companies
in the Global Biotechnology industry.

( Industry Median: 67.35 vs. OCRX: No Debt )
OCRX' s 10-Year Cash to Debt Range
Min: 0.68   Max: No Debt
Current: No Debt

Equity to Asset 0.95
OCRX's Equity to Asset is ranked higher than
97% of the 928 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. OCRX: 0.95 )
OCRX' s 10-Year Equity to Asset Range
Min: -1.09   Max: 0.96
Current: 0.95

-1.09
0.96
F-Score: 4
Z-Score: 19.95
M-Score: 5.01
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -7092.29
OCRX's Operating margin (%) is ranked higher than
52% of the 1027 Companies
in the Global Biotechnology industry.

( Industry Median: -78.88 vs. OCRX: -7092.29 )
OCRX' s 10-Year Operating margin (%) Range
Min: -18034.12   Max: -63.42
Current: -7092.29

-18034.12
-63.42
Net-margin (%) -6938.02
OCRX's Net-margin (%) is ranked higher than
52% of the 1027 Companies
in the Global Biotechnology industry.

( Industry Median: -78.05 vs. OCRX: -6938.02 )
OCRX' s 10-Year Net-margin (%) Range
Min: -20604.71   Max: -77.84
Current: -6938.02

-20604.71
-77.84
ROE (%) -61.48
OCRX's ROE (%) is ranked higher than
65% of the 1143 Companies
in the Global Biotechnology industry.

( Industry Median: -35.75 vs. OCRX: -61.48 )
OCRX' s 10-Year ROE (%) Range
Min: -236.08   Max: -236.08
Current: -61.48

ROA (%) -56.54
OCRX's ROA (%) is ranked higher than
62% of the 1250 Companies
in the Global Biotechnology industry.

( Industry Median: -28.24 vs. OCRX: -56.54 )
OCRX' s 10-Year ROA (%) Range
Min: -87.61   Max: -15.31
Current: -56.54

-87.61
-15.31
ROC (Joel Greenblatt) (%) -13394.90
OCRX's ROC (Joel Greenblatt) (%) is ranked higher than
53% of the 1223 Companies
in the Global Biotechnology industry.

( Industry Median: -438.40 vs. OCRX: -13394.90 )
OCRX' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -46451.52   Max: -526.49
Current: -13394.9

-46451.52
-526.49
Revenue Growth (%) -97.60
OCRX's Revenue Growth (%) is ranked higher than
56% of the 723 Companies
in the Global Biotechnology industry.

( Industry Median: -2.20 vs. OCRX: -97.60 )
OCRX' s 10-Year Revenue Growth (%) Range
Min: 0   Max: -97.6
Current: -97.6

EBITDA Growth (%) -82.20
OCRX's EBITDA Growth (%) is ranked higher than
50% of the 710 Companies
in the Global Biotechnology industry.

( Industry Median: -5.80 vs. OCRX: -82.20 )
OCRX' s 10-Year EBITDA Growth (%) Range
Min: 0   Max: -82.2
Current: -82.2

EPS Growth (%) -84.10
OCRX's EPS Growth (%) is ranked higher than
51% of the 728 Companies
in the Global Biotechnology industry.

( Industry Median: -7.40 vs. OCRX: -84.10 )
OCRX' s 10-Year EPS Growth (%) Range
Min: 0   Max: -84.1
Current: -84.1

» OCRX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2013

OCRX Guru Trades in Q4 2013

Jim Simons 13,949 sh (New)
» More
Q1 2014

OCRX Guru Trades in Q1 2014

Jim Simons 37,049 sh (+165.6%)
» More
Q2 2014

OCRX Guru Trades in Q2 2014

Jim Simons 63,749 sh (+72.07%)
» More
Q3 2014

OCRX Guru Trades in Q3 2014

Jim Simons 38,149 sh (-40.16%)
» More
» Details

Insider Trades

Latest Guru Trades with OCRX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Guru Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Top Ranked Articles about Ocera Therapeutics Inc

Three Insider Buys at 52-Week Lows
Over the past month three companies have reported insider buys as their price hits or nears 52-week lows. Looking at insider buys while they’re trading at low prices can offer an excellent time to buy into a company or further your research on the company. Peter Lynch once offered that insiders will sell their shares in a company for many reasons, but they will only invest it if they think that the share price will rise.

Read more...

Ratios

vs
industry
vs
history
P/B 2.06
OCRX's P/B is ranked higher than
89% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 6.13 vs. OCRX: 2.06 )
OCRX' s 10-Year P/B Range
Min: 0.98   Max: 10.49
Current: 2.06

0.98
10.49
P/S 249.84
OCRX's P/S is ranked higher than
65% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 28.86 vs. OCRX: 249.84 )
OCRX' s 10-Year P/S Range
Min: 0.06   Max: 794
Current: 249.84

0.06
794
EV-to-EBIT -2.22
OCRX's EV-to-EBIT is ranked higher than
72% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. OCRX: -2.22 )
OCRX' s 10-Year EV-to-EBIT Range
Min: -19.2   Max: -1.4
Current: -2.22

-19.2
-1.4
Current Ratio 18.99
OCRX's Current Ratio is ranked higher than
95% of the 1238 Companies
in the Global Biotechnology industry.

( Industry Median: 4.74 vs. OCRX: 18.99 )
OCRX' s 10-Year Current Ratio Range
Min: 0.62   Max: 21.99
Current: 18.99

0.62
21.99
Quick Ratio 18.99
OCRX's Quick Ratio is ranked higher than
95% of the 1238 Companies
in the Global Biotechnology industry.

( Industry Median: 4.57 vs. OCRX: 18.99 )
OCRX' s 10-Year Quick Ratio Range
Min: 0.62   Max: 21.99
Current: 18.99

0.62
21.99

Valuation & Return

vs
industry
vs
history
Price/Net Cash 2.15
OCRX's Price/Net Cash is ranked higher than
96% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 50.00 vs. OCRX: 2.15 )
OCRX' s 10-Year Price/Net Cash Range
Min: 1.54   Max: 10.42
Current: 2.15

1.54
10.42
Price/Net Current Asset Value 2.15
OCRX's Price/Net Current Asset Value is ranked higher than
96% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 29.38 vs. OCRX: 2.15 )
OCRX' s 10-Year Price/Net Current Asset Value Range
Min: 1.49   Max: 10.25
Current: 2.15

1.49
10.25
Price/Tangible Book 2.08
OCRX's Price/Tangible Book is ranked higher than
92% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 9.38 vs. OCRX: 2.08 )
OCRX' s 10-Year Price/Tangible Book Range
Min: 1.24   Max: 7.99
Current: 2.08

1.24
7.99
Price/Median PS Value 95.00
OCRX's Price/Median PS Value is ranked higher than
66% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 2.20 vs. OCRX: 95.00 )
OCRX' s 10-Year Price/Median PS Value Range
Min: 0.01   Max: 81.67
Current: 95

0.01
81.67
Earnings Yield (Greenblatt) -45.00
OCRX's Earnings Yield (Greenblatt) is ranked higher than
52% of the 1218 Companies
in the Global Biotechnology industry.

( Industry Median: -6.30 vs. OCRX: -45.00 )
OCRX' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0   Max: 0
Current: -45

Business Description

Industry: Biotechnology » Biotechnology
Compare: » details
Traded in other countries:6TY1.Germany,
Ocera Therapeutics Inc was incorporated on December 20, 2004. The Company is a clinical stage biopharmaceutical company focused on the development and commercialization of a clinical candidate, OCR-002, for the treatment of hepatic encephalopathy, or HE. HE is a serious complication of liver failure marked by mental changes including confusion, impaired motor skills, disorientation in time and space, and, in its more severe form, stupor, coma and even death. Common causes of liver malfunction leading to HE include alcoholism and hepatitis as well as obesity, Type II diabetes, and acetaminophen overdose. OCR-002 is an ammonia scavenger which has been granted Orphan Disease and Fast Track status from the FDA to treat hyperammonemia and associated hepatic encephalopathy in patients with liver cirrhosis, acute liver failure and acute liver injury. The Company faces competition from established pharmaceutical and biotechnology companies, as well as from academic institutions, government agencies and private and public research institutions, among others, which may in the future develop products to treat HE. The Company is subject to numerous federal, state and local laws relating to such matters as safe working conditions, manufacturing practices, environmental protection, fire hazard control, and disposal of hazardous or potentially hazardous substances.
» More Articles for OCRX

Headlines

Articles On GuruFocus.com
Three Insider Buys at 52-Week Lows Jul 22 2014 
Weekly CEO Buys Highlight: OPK, QTET, MIC, FAST, OCRX Jul 21 2014 
Top 3 Insider Buys of the Week Jul 19 2013 

More From Other Websites
Nasdaq stocks posting largest percentage decreases Dec 17 2014
OCERA THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial... Dec 04 2014
Ocera Therapeutics Promotes Michael Byrnes to Chief Financial Officer Dec 03 2014
Ocera Therapeutics Promotes Michael Byrnes to Chief Financial Officer Dec 03 2014
Ocera Therapeutics (OCRX) Shares March Higher, Can It Continue? Nov 25 2014
Ocera Therapeutics (OCRX) Worth Watching: Stock Up 9.4% Nov 24 2014
OCERA THERAPEUTICS, INC. Financials Nov 21 2014
4 More Biotech Stocks to Buy, With Up to 200% Upside Nov 21 2014
10-Q for Ocera Therapeutics, Inc. Nov 15 2014
Ocera Reports Third Quarter 2014 Financial Results Nov 13 2014
OCERA THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition,... Nov 13 2014
Ocera Reports Third Quarter 2014 Financial Results Nov 13 2014
Ocera Therapeutics to Present at Stifel 2014 Healthcare Conference Nov 10 2014
Ocera Therapeutics to Present at Stifel 2014 Healthcare Conference Nov 10 2014
Ocera Therapeutics to Announce Third Quarter 2014 Financial Results Nov 04 2014
Ocera Therapeutics to Announce Third Quarter 2014 Financial Results Nov 04 2014
Ocera Therapeutics to Present at 13th Annual BIO Investor Forum Sep 29 2014
OCERA THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial... Sep 22 2014
Ocera Therapeutics Announces Appointment of Steven P. James to Board Sep 18 2014
Why You Shouldn't Bet Against Ocera Therapeutics (OCRX) Stock Sep 11 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK